Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

PURPOSE: Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for treatment of advanced prostate cancer, is manufactured by activating peripheral blood mononuclear cells, including antigen presenting cells (APCs), with a fusion protein containing prostatic acid phosphatase. Analysi...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sheikh, Nadeem A., Petrylak, Daniel, Kantoff, Philip W., dela Rosa, Corazon, Stewart, Frances P., Kuan, Ling-Yu, Whitmore, James B., Trager, James B., Poehlein, Christian H., Frohlich, Mark W., Urdal, David L.
Format: Artigo
Langue:Inglês
Publié: Springer-Verlag 2012
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3541926/
https://ncbi.nlm.nih.gov/pubmed/22865266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-012-1317-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires